Glutamatergic Modulation of Motivation Enhancement: A Pilot Feasibility Trial

Phase 1

Completed

• Conditions: Cocaine Use Disorders
• Interventions: Drug: infusion of NMDA antagonist

• Registration Number: NCT02373124
• Lead Sponsor: New York State Psychiatric Institute

Brief Summary

This study evaluates the feasibility of a treatment paradigm that involves naturalistic cocaine use opportunities in the context of psychotherapy aimed at utilizing these opportunities therapeutically.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-12
• Study First Submitted: 2015-01-30
• Study First Submitted QC: 2015-02-20
• Study First Posted: 2015-02-26
• Primary Completion: 2016-10
• Study Completion: 2016-10
• Results First Submitted: 2019-01-25
• Results First Submitted QC: 2019-04-02
• Results First Posted: 2019-04-24
• Status Verified: 2020-01
• Last Update Submitted: 2020-01-30
• Last Update Posted: 2020-02-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 4

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
open-label	infusion of NMDA antagonist	52 minute infusion of NMDA antagonist

Primary Outcome Measures

Name	Time	Method
Cocaine Use	5 weeks	Participants were provided choices to use up to 5 hits of cocaine on up to 2 occasions (cocaine versus money). Participants who chose cocaine (1 or more hits) during the first choice opportunity are administered a 52 minute infusion of 0.71 mg/kg ketamine the following day. Another choice opportunity occurs 24 hours later. The primary outcome is the choice participants made during these occasions

Trial Locations

Locations (1)

New York State Psychiatric Institute; 🇺🇸 New York, New York, United States